Search clinical trials for: H9N2 virosomal vaccine, IM, 5microg

Total 113 results

University Hospitals, Leicester
Public Health England; Crucell Holland BV; National Institute of Biological Standards...

Completed

Safety and Immunogenicity of Influenza H9 Vaccine in Humans

Influenza

United Kingdom
GlaxoSmithKline

Completed

Study to Evaluate the Safety and Immunogenicity of GlaxoSmithKline (GSK) Biologicals' Influenza Vaccines GSK2654911A and GSK2654909A Administered to Adults 18 to 64 Years of Age

Influenza

United States, Canada
FluGen Inc
United States Department of Defense

Completed

Safety and Immunogenicity of Cam2020 M2SR H3N2 Monovalent Influenza Vaccine Alone or With Licensed IIV in Older Adults

Influenza Vaccine

United States
FluGen Inc

Completed

Safety and Immunogenicity of the Bris10 M2SR and Sing2016 M2SR H3N2 Monovalent Influenza Vaccines

Influenza A

United States
NovaDigm Therapeutics, Inc.
United States Department of Defense

Completed

Effect of Adjuvant & Route of Administration on Safety & Immunogenicity of NDV-3 Vaccine

Candidiasis | Staphylococcal Infections | Yeast Infections

United States
The University of Hong Kong

Recruiting

Intradermal COVID-19 Vaccination in the Immunocompromised

Immunocompromised Patients | Intradermal Covid-19 Vaccine | Immungenicity and Safety | Randomized Trial

Hong Kong
National Institute of Allergy and Infectious Diseases...

Completed

Inactivated Influenza A/H9N2 Vaccine With and Without MF59 Adjuvant in Ambulatory Adults

Influenza

United States
U.S. Army Medical Research and Development Command

Active, not recruiting

Combination HTNV and PUUV DNA Vaccine

Hantaan Virus Disease, Puumala Virus

United States
Ology Bioservices

Completed

Reverse Genetic H9N2 Influenza Vaccine Study in Adults

Influenza

United States
Stanford University
National Institute of Allergy and Infectious Diseases (NIAID)

Completed

Comparison of Immune Responses to Influenza Vaccine In Adults of Different Ages (SLVP015 2007-2017)

Influenza

United States
PATH
Institute of Experimental Medicine, Russia; Ministry of Health, Russian Federation

Completed

Reactogenicity, Safety and Immunogenicity of a Live Monovalent A/17/CALIFORNIA/66/395 (H2N2) Influenza Vaccine

Influenza

Russian Federation
National Institute of Allergy and Infectious Diseases...

Completed

H9 Priming Study in Healthy Adults

Influenza

United States
PATH
Institute of Experimental Medicine, Russia; Microgen

Completed

Reactogenicity, Safety, and Immunogenicity of a Live Monovalent H5N2 Influenza Vaccine

Influenza

Russian Federation
Sanofi Pasteur, a Sanofi Company
Sanofi K.K.

Completed

Safety and Immunogenicity of High-Dose Quadrivalent Influenza Vaccine in Patients ≥65 Years

Influenza

Japan
Masonic Cancer Center, University of Minnesota

Terminated

Influenza Vaccine Post Allogeneic Transplant

Hematologic Malignancy | Hematopoietic Stem Cell Transplant

United States
Rockefeller University

Active, not recruiting

An Open Label Study of IgG Fc Glycan Composition in Human Immunity

Healthy

United States
Crucell Holland BV

Completed

Immunogenicity and Safety Study to Assess Influenza Vaccine Formulated With Haemagglutinin (HA) Antigen From Two Different Suppliers

Influenza

Switzerland
University Hospital Inselspital, Berne
Merck Sharp & Dohme LLC; Boehringer Ingelheim; Abbott; Solvay Pharmaceuticals

Completed

Influenza Vaccination in Immunocompromized Patients

Immunosuppression

Switzerland
Sinovac Biotech (Hong Kong) Limited

Completed

Immunogenicity and Safety Study of Booster Vaccine With the COVID-19 Vaccine (Vero Cell), Inactivated, Omicron Strain

COVID-19

China
Barbara Ensoli, MD
Novartis Vaccines

Terminated

A Phase I Safety and Immunogenicity Preventive Vaccine Trial Based on the HIV-1 Tat and V2-deleted Env Proteins (ISS P-002)

HIV Infection

Italy
National Institute of Allergy and Infectious Diseases...

Completed

Safety and Immunogenicity of a Monovalent Inactivated Influenza H3N2 Variant (H3N2v) Vaccine in Adult and Elderly Populations

Influenza

United States
Crucell Holland BV

Completed

Safety, Tolerability, and Immunogenicity Study of a Cell-based Virosomal Influenza Vaccine in Healthy Adults

Influenza

Belgium
National Institute of Allergy and Infectious Diseases...
Johns Hopkins Bloomberg School of Public Health

Completed

Safety and Immune Response to Recombinant Live-Attenuated Influenza H2N2 Virus Vaccine

Virus Diseases | Influenza

United States
National Institute of Allergy and Infectious Diseases...

Completed

Higher Dose Intradermal H5 Vaccine

Influenza

United States
PATH
Institute of Experimental Medicine, Russia; Research Institute of Influenza...

Completed

Immunogenicity of H5N1 Vaccine Following H5N2

Influenza Vaccine

Russian Federation
University of Sydney
Telethon Kids Institute; Bionet Co., Ltd; Technovalia; Institute for Clinical Pathology...

Completed

The Safety and Immunogenicity of a DNA-based Vaccine (COVIGEN) in Healthy Volunteers (COVALIA)

SARS-CoV2 COVID-19

Australia
Catholic Kwandong University
Korea University Guro Hospital

Active, not recruiting

Immunogenicity of Concomitant Administration of COVID-19 Vaccines With Influenza Vaccines

COVID-19 | Vaccine Reaction | Influenza | Contaminant Injected

Korea, Republic of
National Institute of Allergy and Infectious Diseases...

Completed

H3N2 M2SR in Pediatric Population

Influenza | Influenza Immunisation

United States
FluGen Inc

Completed

Safety and Immunogenicity Study of H3N2 M2SR Monovalent Influenza Vaccine in Healthy Volunteers

Flu

United States
China National Biotec Group Company Limited
The University of Hong Kong; Beijing Institute of Biological Products Co Ltd.; Wuhan Institute of Biological Products Co., Ltd

Active, not recruiting

Sequential Immunization of Two Doses of Inactivated COVID-19 Vaccine (Omicron) in Vaccinated Population Aged 18 Years and Above (COVID-19)

COVID-19

Hong Kong
London School of Hygiene and Tropical Medicine

Completed

IPV Clinical Trial - The Gambia (IPV)

Poliomyelitis

Gambia
National Institute of Allergy and Infectious Diseases...

Withdrawn

Pharma-Pen (Formerly Innoject) Auto-injectory TIV

Influenza

United States
National Institute of Allergy and Infectious Diseases...
University of Rochester

Completed

Study of Immune Responses in Healthy Adults Receiving Live Influenza Virus Vaccines

Influenza, Human

United States
FluGen Inc
National Institute of Allergy and Infectious Diseases (NIAID)

Completed

Safety and Immunogenicity of the Sing2016 M2SR H3N2 Monovalent Influenza Vaccine in Adults Ages 50 to 85 Years Old

Influenza Vaccine

United States
Stanford University
National Institute of Allergy and Infectious Diseases (NIAID)

Completed

Plasmablast Trafficking and Antibody Response in Influenza Vaccination (SLVP021 2011-2014)

Influenza

United States
Washington University School of Medicine

No longer available

Expanded Access Neoantigen Vaccine in Solid Tumors

Solid Tumor, Adult

United States
Pontificia Universidad Catolica de Chile
Sinovac Life Sciences Co., Ltd.

Completed

Immunogenicity Evaluation of Omicron Variant-based Vaccine and a Trivalent Vaccine in Adults Against COVID-19 in Chile (CoronaVarCL)

COVID-19 | Vaccines

Chile
Catholic Kwandong University
Korea University Guro Hospital

Completed

Immunogenicity and Safety of Concomitant Administration of Bivalent COVID-19 Vaccines With Influenza Vaccines

Immune Response | Safety

Korea, Republic of
Bayside Health
Monash University

Recruiting

Bringing Optimised COVID-19 Vaccine Schedules To ImmunoCompromised Populations (BOOST-IC): an Adaptive Randomised Controlled Clinical Trial

Lymphoma, Non-Hodgkin | Multiple Myeloma | HIV | Chronic Lymphocytic Leukemia | Organ Transplantation | COVID-19 Vaccines

Australia
China National Biotec Group Company Limited
Beijing Institute of Biological Products Co Ltd.; Hunan Provincial Center for...

Active, not recruiting

Study on Sequential Immunization of Omicron Inactivated COVID-19 Vaccine and Prototype Inactivated COVID-19 Vaccine in Population Aged 18 Years Old and Above (COVID-19)

COVID-19

China
AIM Vaccine Co., Ltd.
First Affiliated Hospital Bengbu Medical College; Ningbo Rongan Biological...

Active, not recruiting

A Preliminary Exploratory Cohort Study of COVID-19 mRNA Vaccine, Bivalent in Participants Aged 18 Years and Over in China

SARS-CoV-2

China
GlaxoSmithKline

Completed

Safety and Immunogenicity of FluLaval™ TR and Fluarix® (Influenza Vaccines) in Young and Older Adults

Influenza

United States
Anhui Zhifei Longcom Biologic Pharmacy Co., Ltd.
First Affiliated Hospital Bengbu Medical College

Completed

Recombinant Omicron-Delta COVID-19 Vaccine (CHO Cell)

COVID-19

China
Washington University School of Medicine
National Cancer Institute (NCI)

Terminated

Neoantigen DNA Vaccine in Pancreatic Cancer Patients Following Surgical Resection and Adjuvant Chemotherapy

Pancreatic Cancer | Pancreas Cancer | Cancer of the Pancreas

United States
Crucell Holland BV

Completed

Re-licensing Study to Assess Virosomal Influenza Vaccine Formulated With WHO Recommended Influenza Strains

Influenza

Switzerland
AIM Vaccine Co., Ltd.
First Affiliated Hospital Bengbu Medical College; Ningbo Rongan Biological...

Not yet recruiting

A Cohort Study of SARS-CoV-2 Variant (Omicron BA.5) mRNA Vaccine in Participants Aged 18 Years and Over in Chinese People

SARS-CoV-2
AIM Vaccine Co., Ltd.
First Affiliated Hospital Bengbu Medical College; Ningbo Rongan Biological...

Active, not recruiting

A Preliminary Exploratory Cohort Study of SARS-CoV-2 Variant (Omicron BA.5) mRNA Vaccine in Participants Aged 18 Years and Over in China

SARS-CoV-2

China
Novavax

Completed

A Study to Evaluate the Safety and Immunogenicity of an (Omicron Subvariant) COVID-19 Vaccine Booster Dose in Previously Vaccinated Participants and Unvaccinated Participants. (COVID-19)

COVID-19

United States
Washington University School of Medicine
Children's Discovery Institute

Not yet recruiting

Neoepitope-based Personalized DNA Vaccine Approach in Pediatric Patients With Recurrent Brain Tumors

Pediatric Recurrent Brain Tumor

United States
Assistance Publique - Hôpitaux de Paris
IREIVAC/COVIREIVAC Network

Active, not recruiting

Immunogenicity and Reactogenicity of the Beta-variant Recombinant Protein Booster Vaccine (VidPrevtyn Beta, Sanofi) Compared to a Bivalent mRNA Vaccine (Comirnaty Original/Omicron BA.4-5, BioNTech-Pfizer) in Adults Previously Vaccinated With at Least 3 Doses of COVID-19 mRNA Vaccine (CoviBOOST 2)

COVID-19 | Vaccine Reaction

France

Search clinical trials for: H9N2 virosomal vaccine, IM, 5microg

Sponsors and Collaborators

Medical Conditions

Drug Interventions

CROs by country

CROs in Uganda

Conditions

Rare Diseases

Drug Interventions

Dietary Supplements

Sponsor/Collaborators

Locations